617 related articles for article (PubMed ID: 22402936)
61. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
62. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
[TBL] [Abstract][Full Text] [Related]
63. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
64. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
65. Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis.
Palus M; Zampachová E; Elsterová J; Růžek D
J Infect; 2014 Feb; 68(2):165-9. PubMed ID: 24091083
[TBL] [Abstract][Full Text] [Related]
66. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
[TBL] [Abstract][Full Text] [Related]
67. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
[TBL] [Abstract][Full Text] [Related]
68. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma.
Ulrich D; Noah EM; von Heimburg D; Pallua N
Plast Reconstr Surg; 2003 Apr; 111(4):1423-31. PubMed ID: 12618601
[TBL] [Abstract][Full Text] [Related]
69. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia.
Myers JE; Merchant SJ; Macleod M; Mires GJ; Baker PN; Davidge ST
Hypertens Pregnancy; 2005; 24(2):103-15. PubMed ID: 16036395
[TBL] [Abstract][Full Text] [Related]
70. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders.
Hurnaus S; Mueller-Felber W; Pongratz D; Schoser BG
Eur Neurol; 2006; 55(4):204-8. PubMed ID: 16772717
[TBL] [Abstract][Full Text] [Related]
71. Elevated levels of MMP-9 in untreated patients with stage I essential hypertension.
Gkaliagkousi E; Doumas M; Gavriilaki E; Triantafyllou A; Vogiatzis K; Anyfanti P; Petidis K; Douma S
Clin Exp Hypertens; 2012; 34(8):561-6. PubMed ID: 22574960
[TBL] [Abstract][Full Text] [Related]
72. Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study.
Louhelainen N; Stark H; Mazur W; Rytilä P; Djukanovic R; Kinnula VL
BMC Pulm Med; 2010 Mar; 10():13. PubMed ID: 20226090
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
[TBL] [Abstract][Full Text] [Related]
74. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
[TBL] [Abstract][Full Text] [Related]
75. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia.
Chiang TY; Yu YL; Lin CW; Tsao SM; Yang SF; Yeh CB
Clin Chim Acta; 2013 Sep; 424():261-6. PubMed ID: 23792071
[TBL] [Abstract][Full Text] [Related]
76. Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level.
Komosinska-Vassev K; Olczyk P; Winsz-Szczotka K; Kuznik-Trocha K; Klimek K; Olczyk K
Gerontology; 2011; 57(1):44-52. PubMed ID: 20215736
[TBL] [Abstract][Full Text] [Related]
77. Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers.
Li Z; Guo S; Yao F; Zhang Y; Li T
J Diabetes Complications; 2013; 27(4):380-2. PubMed ID: 23357650
[TBL] [Abstract][Full Text] [Related]
78. Altered circulating levels of matrix metalloproteinases 2 and 9 and their inhibitors and effect of progesterone supplementation in women with endometriosis undergoing in vitro fertilization.
Singh AK; Chattopadhyay R; Chakravarty B; Chaudhury K
Fertil Steril; 2013 Jul; 100(1):127-34.e1. PubMed ID: 23557756
[TBL] [Abstract][Full Text] [Related]
79. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.
Kuliczkowski W; Urbaniak J; Hallén J; Woźniak M; Poloński L; Mysiak A; Atar D; Zembala M; Serebruany V
Kardiol Pol; 2013; 71(5):453-63. PubMed ID: 23788085
[TBL] [Abstract][Full Text] [Related]
80. Simvastatin therapy decreases MMP-9 levels in obese women.
Andrade VL; do Valle IB; Sandrim VC
J Clin Pharmacol; 2013 Oct; 53(10):1072-7. PubMed ID: 23913656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
